Breaking News
Get 55% Off 0
Get Premium Data for Cyber Monday: Up to 55% Off InvestingPro
CLAIM SALE
Close

Roche Holding AG Participation (ROGN)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Delivery Method

Status

Add to/Remove from Watchlist Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
5,911.950 +78.610    +1.35%
- Closed. Currency in MXN
Type:  Equity
Market:  Mexico
ISIN:  CH0012032048 
  • Volume: 282
  • Bid/Ask: 5,865.000 / 5,865.000
  • Day's Range: 5,911.950 - 5,942.250
Roche Holding Participation 5,911.950 +78.610 +1.35%

SIX:ROGN Financials

 
Explore the SIX:ROG financials. Find the Roche Holding Participation financial statements for a comprehensive overview of the company’s financial health. This summary highlights critical numbers from key financial reports, including the Roche Holding Participation annual report, the income statement, balance sheet, and cash flow statement. Gain deeper insights with financial ratios that assess the company's performance and stability. Users can customize their view by selecting data from four periods of either annual or quarterly information, making it easy to track the financial performance of Roche Holding Participation over time.

Roche Holding AG reported earnings results for the half year ended June 30, 2024. For the half year, the company reported sales was CHF 29,848 million compared to CHF 29,779 million a year ago. Revenue was CHF 30,756 million compared to CHF 30,616 million a year ago. Net income was CHF 6,258 million compared to CHF 7,137 million a year ago. Basic earnings per share from continuing operations was CHF 7.85 compared to CHF 8.93 a year ago. Diluted earnings per share from continuing operations was CHF 7.8 compared to CHF 8.87 a year ago.

AnnualQuarterly  
Advanced Financial Summary
TTM = Trailing Twelve Months
MRQ = Most Recent Quarter

ROGN Income Statement

Gross margin TTM 74.54%
Operating margin TTM 29.71%
Net Profit margin TTM 17.53%
Return on Investment TTM 24.3%
 Total Revenue  Net Income
Period Ending: Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023
Total Revenue 15378 15378 14912.5 14912.5
Gross Profit 11642 11642 10923.5 10923.5
Operating Income 5423.5 5423.5 3563.5 3563.5
Net Income 3129 3129 2180.5 2180.5

ROGN Balance Sheet

Quick Ratio MRQ 0.79
Current Ratio MRQ 1.26
LT Debt to Equity MRQ 98.2%
Total Debt to Equity MRQ 124.99%
 Total Assets  Total Liabilities
Period Ending: Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023
Total Assets 95786 95786 90468 90468
Total Liabilities 62910 62910 57205 57205
Total Equity 32876 32876 33263 33263

ROGN Cash Flow Statement

Cash Flow/Share TTM 20.21
Revenue/Share TTM 75.99
Operating Cash Flow  14.88%
 Cash  Net Change in Cash
Period Ending: Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023
Period Length: 0 Months 0 Months 0 Months 0 Months
Cash From Operating Activities 3957 3957 4098.5 4098.5
Cash From Investing Activities -1432.5 -1432.5 -5080.5 -5080.5
Cash From Financing Activities -2724.5 -2724.5 2027 2027
Net Change in Cash -276 -276 828 828
* In Millions of CHF (except for per share items)
InvestingPro
Go to Dashboard InvestingPro

Unlock access to over 1000 metrics with InvestingPro

View advanced insights on financial statements, including growth rates and metrics that provide an in-depth view of the company's historical and forecasted financial performance.

 
Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.
  • Any comment you publish, together with your investing.com profile, will be public on investing.com and may be indexed and available through third party search engines, such as Google.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

ROG Comments

Write your thoughts about Roche Holding AG Participation
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
Mikel ibanez
Mikel ibanez Dec 04, 2023 6:55AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
18 per and 4% dividend starts looking good. Long hold and nice life investment in one of Europe best companies in a non hype sector
BOXING HUANG
BOXING HUANG Oct 19, 2023 6:13AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
What happened today?
Giancarlo Velotti
Giancarlo Velotti Jul 13, 2023 3:17AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
It is a buy at 266
taja maja
taja maja Jan 26, 2023 2:25PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
When ist best time to buy?
Scott Goldie
Scott Goldie Jan 17, 2023 5:48PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
SP suffering since May 2022 due to decline in COVID vaccines.
Jonah Garber
Jonah Garber Jul 24, 2022 12:17PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
macd indicators showing a nice jump coming, keeping my fingers crossed during these dark times
BOXING HUANG
BOXING HUANG May 11, 2022 4:13AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
What happened today?
Tvynis Jutvynis
Tvynis Jutvynis May 11, 2022 4:13AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
The SKYSCRAPER-01 study evaluating tiragolumab plus Tecentriq did not meet its co-primary endpoint of progression-free survival
Tvynis Jutvynis
Tvynis Jutvynis May 11, 2022 4:13AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Today only this info about Roche
Sherlyn Jones
Sherlyn Jones Apr 22, 2021 6:48AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
A large pharmaceutical company, by the name of R. , is pushing down the value of the Spanish company's Pharmamar share price through the funds Consonance Capital and Great Point Partners, so that the biotech company accepts its offer of more than 4500 million dollars.According to this pharma, Pharmamar's products have a great future in oncology and virology, and would be fully engaged in its search for new drugs.
Financial Advisors
Financial Advisors Apr 22, 2021 6:48AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
hello to Marinopoulos Pharma company .!
José Spescha
José Spescha Mar 18, 2021 4:32AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Trades ex dividend!!
Victor Garcia
Victor Garcia Feb 01, 2021 2:38PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Currently near to Fibo 61.8 levels, a great company to buy IMO.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Apple
Continue with Google
or
Sign up with Email